Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rizatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 7/20 | 0.80 |
| ▸ | HTR1B known ✓ | P28222 | 7/20 | 0.80 |
| ▸ | HTR1A | P08908 | 10/20 | 0.80 |
| ▸ | HTR2C | P28335 | 7/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | HRH1 | P35367 | 1/20 | 0.80 |
| ▸ | HTR2B | P41595 | 1/20 | 0.80 |
| ▸ | HTR5A | P47898 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rizatriptan SCHEMBL4714817 | 1.00 | HTR1A (0.80) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL41226 | 1.00 | HTR1A (0.80) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL27885182 | 0.91 | HTR1A (0.75) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL8809854 | 0.91 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL8809846 | 0.91 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL3462253 | 0.90 | HTR1A (0.85) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL29407208 | 0.89 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL12802834 | 0.89 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL26662 | 0.89 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL2326617 | 0.89 | HTR1A (0.83) | HTR1AHTR2CHTR1DHTR1BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536368-B1 | DRY POWDER INHALER COMPRISING A SEROTONIN RECEPTOR AGONIST AND A DIKETOPIPERAZINE FOR TREATING MIGRAINES | MANNKIND CORP (US) | 2025-09-17 | — | — | EP | claimed |
| CN-119662465-A | Composite starter and high-calcium yoghourt containing vitamin K2 | 重庆市天友乳业股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240382438-A1 | Calcium Channel Blockers and Methods Thereof | UNIV OF MARYLAND EASTERN SHORE (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118325756-A | Lactobacillus bulgaricus and application thereof | 重庆市天友乳业股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3299010-B1 | ORAL DOSAGE FORM | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2022-11-09 | — | — | EP | disclosed |
| US-7786156-B2 | Synthesis methods and intermediates for the manufacture of Rizatriptan | RATIOPHARM GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| EP-1751104-B1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE MANUFACTURE OF RIZATRIPTAN | RATIOPHARM GMBH (DE) | 2010-03-24 | — | — | EP | disclosed |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | RATIOPHARM GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1751104-A1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE MANUFACTURE OF RIZATRIPTAN | ratiopharm GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005075422-A1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE MANUFACTURE OF RIZATRIPTAN | RATIOPHARM GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382438-A1 | Calcium Channel Blockers and Methods Thereof | CACNB2, CACNA1B, CACNB1 | HTR1D 1725/4885HTR1B 447/4885HTR1A 917/4885 |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | HTR7, HRH4, CA7 | HTR1D 48/4885HTR1B 147/4885HTR1A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.